Results from a phase III COVID-19 study showed that oral sabizabulin, a novel dual antiviral and anti-inflammatory agent, improved outcomes in hospitalized moderate-to-severe COVID-19 patients at high risk for acute respiratory distress syndrome and death.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
